We use cookies to customise content for your subscription and for analytics.If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Biotech secures $5.3 million for immunosuppressant drug research

San Francisco-based startup, Nurix, Inc., which reportedly develops T-cellspecific immunosuppressants used to treat autoimmune diseases such as rheumatoid arthritis, lupus, multiple sclerosis, and psoriasis, has evidently secured $5.3 million in equity funding from four investors, according to a securities filing. Nurix is apparently backed by a group of venture investors, including The Column Group and Third Rock Ventures. See MedCity News, April 4, 2013.